Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Merger or Acquisition (July 2005)
16 slides from Teva Pharmaceutical Industries's merger presentation, Jul 26, 2005
Slide 1: Teva Pharmaceutical Industries Ltd. - July 2005 Investor Presentation
Filed by: Teva Pharmaceutical Industries Limited Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Ivax Corporation Commission File No. 001-09623 The following slides were part of a presentation
Slide 2: Today's Presentation Contains Forward-Looking Statements
TODAY’S STATEMENTS FUTURE SUCH SUCCESSFULLY OF BRANDED THE PHARMACEUTICAL BEING DEPENDENCE RESULTS, COMMISSION TO 2 COMPETITION UPDATE CURRENT REGULATORY FORWARD-LOOKING SOLD RESULTS, PRESENTATION OTHER PRODUCT, PUBLICLY OR ARE (“SEC”). ON INSURANCE DEVELOP IN FACTORS PATENT FROM BASED PERFORMANCE E
Slide 3: Teva Acquisition of Ivax: Transaction Overview
Teva Acquisition Transaction Complementary 3 Overview Businesses, of Ivax Strategic Geographies Rationale and Financial Technologies BenefitsA Leading Generic Company Summary
Slide 4: Transaction Overview
Transaction Teva Financed Combination 25,000 Creates Annual 4 to employees run-rate acquire cost withOverview and brings aIvax of combination sales sales together for synergies approximately at closing complementary of equity, in expected generics $7.4 debtand to billion and products, exceed innovat
Slide 5: Strategic Rationale
Strategic Brings and Enhances Ability 5 Ivax) together toRationale leadership vertical respond, exciting integration onposition a global prospects between inscale, thefor US, togrowth, API the expands (active widest with strong pharmaceutical range new presence proprietary of requirements iningredie
Slide 6: Financial Benefits and Synergies
Financial Transaction Ample Synergies Sales 6 synergies opportunities Benefits will expected come Complementary from for to become synergies efficiencies distribution accretive of upin to manufacturing, to$150 earnings million within by SG&A the first end and year ofR&D the aftersecond Consolidation
Slide 7: Complementary Businesses: Revenue by Product Type
Complementary Teva 2004 ($ 78% 11% 34% 66% API 75% 9% 8% (1) 7 in& –$4,966 Innovative Branded Generic $4,799 millions) Revenue Other Figures $3,749 $1,217 $620 $527Contribution Businesses million $523 by are basedIvax Product onAnalysis Type– $1,837available publicly million Pro Forma – $6,636 milli
Slide 8: Complementary Geographies and Portfolio
Complementary Strengthens Enhances Obtains Builds 8 leading leadership current leadership presence Geographies leadership position ininUS Latin inposition generics France, America inRussia Portfolio theincluding UKand Pipeline Czech Venezuela, Technologies Republic Chile andand gains Peru strong and
Slide 9: Complementary Geographies: Revenue by Region
Complementary ($ Teva 9 in millions) 2004 10% 64% Latin 46% 37% 17% Europe ROW 29% North 59% 12% (1) (2) –$1,245 $4,799 Revenue $495 America America $811 $704 $1,949 by Excludes Figures Geographies million 26% $316 $3,059 $860 $3,919 $42.1 are based Ivax Geography – in million $1,880 million(1) Ivax
Slide 10: Complementary Technologies
Complementary Combined Tablets Controlled 10 Capsules technology release Technologies Ointments coverage Creams includes Liquids Suspensions Soft gels Injectibles Metered dose inhalers Nasal sprays Breath actuated inhalers Breath operated inhalers
Slide 11: Global Generic Pipeline and Shared Value
GlobalinGeneric Value Shared Opportunities 11 broad combined line toResearch leverage philosophy pipeline & development Increased Development Strong scientific filings acrossatmarkets capabilities FDA Complementary Exploit and centers technology therapeutic of excellence across areas markets Increas
Slide 12: Expanded Proprietary Branded Pipeline
Expanded Maintain market Copaxone- MS Teva Oral Other targeted MS Therapeutic leaderpresence candidates Agilect/Azilect Neurology Pipeline Autoimmune for targeting Proprietary in key include Parkinson’s Alzheimer’s branded Portfolio Copaxone areas and Laquinimod Lupus Oncology Unique Respiratory Iva
Slide 13: A Leading Generic Company
A Leading Top ($ Sales KGaA Merck Sandoz+Hexal+Eon Teva+Ivax Company 13 in8millions) Alpha $M Source: Ranbaxy Mylan generic Ratiopharm rma $7,000 Generic Watson drug financial $6,000 manufacturers Company reports;$5,000 $4,000 (based Ratiopharm $3,000 on 2004 $2,000 sales)$1,000 sales—company websit
Slide 14: Financial Terms of the Transaction
Financial Purchase of 0.4235 with Consideration 14 consideration theTeva same consideration Terms shares terms perof subject share the andTransaction $26 $13 $26.00 to proration, per in cash per IvaxIvax for share, based each share via on Ivax based Ivax cash share shareholders’ election on Election
Slide 15: Combination Summary
Combination Summary Transaction Creates Compelling 15 cost brings financial and strengthens sales together rationale synergies global businesses EPS in leadership generics accretive within and complementary within generics, innovative twelve addsbusinesses months geographies, new product Substantial
Slide 16: Teva Pharmaceutical Industries Ltd.
Pharmaceutical July 2005 Industries Ltd.
Teva Pharmaceutical Industries — Merger or Acquisition (July 2005) on 6ix